The immuno-oncology (I/O) revolution is premised on the idea that the immune system is capable of recognizing tumors and training certain immune cells, called T-cells, to destroy tumors and ensure ...

Drugmakers are quick to cite results from tests for new immuno-oncology meds, with companies such as Bristol-Myers Squibb ($BMY), Merck ($MRK), Roche ($RHHBY) and ...

German and U.S.-based molecular diagnostics firm Epigenomics got FDA approval for its blood-based colorectal cancer screening test. Epigenomics' Epi proColon uses a blood sample to see whether or not ...

Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons learned from the successes with ...

A sensor identifies misfolded protein biomarkers in the blood. This offers a chance to detect Alzheimer's disease before any symptoms occur. Researchers intend to bring it to market maturity. The ...

New research links inflammation to mental health symptoms. Personalized care using brain and immune data could improve ...

A new report, released on the preprint server bioRxiv* by researchers at the Fraunhofer Institute for Molecular Biology and Applied Ecology, describes the development of an innovative serologic test ...

TINLEY PARK, Illinois, March 12, 2019 /PRNewswire/ -- Hematogenix®- a global leader in the field of integrated pathology services for drug development and immuno-oncology testing, today announced the ...

Rolling out disappointing numbers today, Roche CEO Severin Schwan played the immuno-oncology card while trying to make the case that the pharma giant still has a hot hand in the late-stage drug ...

MIAMI & MEMPHIS, Tenn.--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE:OPK) and Immuno Technologies, Inc. today announced that the National Institutes of Health (NIH) has awarded a $3 million grant to ...